Clinical Research Directory

Inclusion Criteria: 1. Male and female participants 18 to 75 years old (inclusive) at Screening Visit 1. 2. ALS diagnosed as laboratory-supported probable, clinically probable, or definite as defined by the revised El Escorial criteria. 3. Having onset of ALS symptoms, including muscle weakness, within 24 months from Screening Visit 1. 4. ≥2 points on each item of the ALSFRS-R at the Screening Visit 1. 5. ≤45 points on ALSFRS-R total score at Screening Visit 1. 6. Upright slow vital capacity (SVC) measure ≥65% of predicted for gender, height, and age at Screening Visit 1. 7. Participants must adhere to highly effective methods of contraception as specified in the study protocol. Exclusion Criteria: 1. Prior stem cell therapy of any kind. 2. Active participation in any other ALS interventional study. 3. Inability to lie flat for the duration of IT cell treatment and/or bone marrow biopsy, or inability to tolerate study procedures for any other reason. 4. Any unstable clinically significant medical condition other than ALS 5. Any history of malignancy, within the previous 5 years, with the exception of localized skin cancers, cervical cancer in-situ or prostate cancer in-situ (with no evidence of metastasis, significant invasion, or reoccurrence within 3 years of baseline). 6. Primary brain cancer or cancer with CNS involvement is exclusionary. 7. Other types of motor neuron disease such as primary lateral sclerosis, progressive muscular atrophy, and progressive bulbar palsy. 8. Usage of a feeding tube at Screening Visit 1 or Screening Visit 2. 9. Pregnant women or women currently breastfeeding.